Trials / Terminated
TerminatedNCT04924192
A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open, multi-cohort, exploratory phase II study on the safety and efficacy of TQB3616 combined with Anlotinib hydrochloride capsules or standard chemotherapy in the treatment of advanced lung cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB3616 capsules | A CDK4/6 kinase inhibitor |
| DRUG | Anlotinib Hydrochloride capsules | A multi-target receptor tyrosine kinase inhibitor |
| DRUG | Irinotecan Hydrochloride for Injection | An inhibitor of DNA topoisomerase Ⅰ |
Timeline
- Start date
- 2021-08-18
- Primary completion
- 2022-09-27
- Completion
- 2022-10-10
- First posted
- 2021-06-11
- Last updated
- 2026-04-13
Locations
7 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04924192. Inclusion in this directory is not an endorsement.